Published in Amino Acids on July 30, 2010
Evaluation of fluorine-labeled gastrin-releasing peptide receptor (GRPR) agonists and antagonists by LC/MS. Amino Acids (2012) 0.77
Rational design of matrix metalloproteinase-13 activatable probes for enhanced specificity. ACS Chem Biol (2013) 0.76
Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter. Nanoscale (2016) 0.75
microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med (2004) 2.05
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res (1999) 1.92
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A (1991) 1.47
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med (2008) 1.34
Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol (2005) 1.29
Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med (2009) 1.29
Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol (2007) 1.28
Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem (2009) 1.26
Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol (1999) 1.15
Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol (2006) 1.15
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res (2004) 1.12
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem (2008) 1.09
[99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging (2002) 1.09
99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem (2008) 0.93
A new in vitro approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations. Rapid Commun Mass Spectrom (2008) 0.92
In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites. Bioconjug Chem (2009) 0.84
Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry. Curr Drug Metab (2008) 0.83
Gastrin-releasing peptide receptor expression in cervical cancer. Oncology (2008) 0.81
Applications of LC-MS in PET radioligand development and metabolic elucidation. Curr Drug Metab (2010) 0.80
High-thermoelectric performance of nanostructured bismuth antimony telluride bulk alloys. Science (2008) 7.34
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol (2008) 6.41
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data. Med Care (2010) 3.71
Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res (2008) 3.47
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol (2002) 2.98
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Nanoparticle-based theranostic agents. Adv Drug Deliv Rev (2010) 2.86
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med (2007) 2.86
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
APPLICATION OF PREPARATIVE HIGH-SPEED COUNTERCURRENT CHROMATOGRAPHY FOR SEPARATION OF ELATINE FROM DELPHINIUM SHAWURENSE. J Liq Chromatogr Relat Technol (2008) 2.49
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 2.31
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett (2010) 2.00
Allocating scarce resources in real-time to reduce heart failure readmissions: a prospective, controlled study. BMJ Qual Saf (2013) 1.94
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc (2008) 1.89
Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 1.87
MyD88 plays a unique role in host defense but not arthritis development in Lyme disease. J Immunol (2004) 1.85
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther (2006) 1.81
Flat-twisted tubing: novel column design for spiral high-speed counter-current chromatography. J Chromatogr A (2009) 1.81
Porcine respiratory and reproductive syndrome virus variants, Vietnam and China, 2007. Emerg Infect Dis (2008) 1.80
Pulse accumulation, radial heat conduction, and anisotropic thermal conductivity in pump-probe transient thermoreflectance. Rev Sci Instrum (2008) 1.80
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
Streptococcus suis enolase functions as a protective antigen displayed on the bacterial cell surface. J Infect Dis (2009) 1.78
Unusual magnetic properties of one-dimensional molecule-based magnets associated with a structural phase transition. Inorg Chem (2002) 1.78
Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem (2006) 1.75
Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc Res (2009) 1.70
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. Chem Rev (2014) 1.68
Novel Design for Centrifugal Countercurrent Chromatography: I. Zigzag Toroidal Column. J Liq Chromatogr Relat Technol (2009) 1.67
Development of a controlled vocabulary and software application to analyze fruit shape variation in tomato and other plant species. Plant Physiol (2006) 1.64
Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem (2007) 1.64
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem (2006) 1.64
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology (2011) 1.59
Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells (2009) 1.58
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem (2011) 1.56
Oxorhenium(V) complexes containing tridentate Schiff-base and monothiol coligands. Inorganica Chim Acta (2000) 1.56
Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater (2012) 1.56
Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging (2008) 1.55
Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res (2005) 1.55
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med (2012) 1.52
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 1.50
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol (2009) 1.49
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
Uncovering newly emerging variants of Streptococcus suis, an important zoonotic agent. Trends Microbiol (2010) 1.46
Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano (2010) 1.46
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med (2013) 1.44
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl (2009) 1.44
Long-term renal changes in the liver-specific glucokinase knockout mouse: implications for renal disease in maturity-onset diabetes of the young 2. Transl Res (2010) 1.44
Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano (2013) 1.44
Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB. Cardiovasc Res (2008) 1.44
Peptide-based probes for targeted molecular imaging. Biochemistry (2010) 1.43
A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging (2007) 1.43
Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials (2009) 1.42
A strategy for the proliferation of Ulva prolifera, main causative species of green tides, with formation of sporangia by fragmentation. PLoS One (2010) 1.42
Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet (2011) 1.42
Integrin targeted delivery of chemotherapeutics. Theranostics (2011) 1.42
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol (2013) 1.39
Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem (2007) 1.39
Evaluation of the effect of column orientation in type-I high-speed counter-current chromatography. J Chromatogr A (2010) 1.39
Ultrasmall near-infrared non-cadmium quantum dots for in vivo tumor imaging. Small (2010) 1.38
18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med (2006) 1.37
Protease-activated drug development. Theranostics (2012) 1.36
Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem (2009) 1.36
PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med (2009) 1.36